Elanco Animal Health (ELAN) Other Non-Current Liabilities (2017 - 2026)
Elanco Animal Health (ELAN) reported Other Non-Current Liabilities of $467.0 million for Q1 2026, down 4.11% on a YoY basis from $487.0 million in Q1 2025, and up 53.62% sequentially from $304.0 million in Q4 2025.
Elanco Animal Health (ELAN) Other Non-Current Liabilities (2017 - 2026) Analysis & Trends
Elanco Animal Health (ELAN) has 10 years of Other Non-Current Liabilities data on file, last reported at $467.0 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities fell 4.11% year-over-year to $467.0 million; the trailing twelve-month figure through Mar 2026 stood at $467.0 million (down 4.11% YoY), and the FY2025 full-year result was $304.0 million, up 0.66% from the prior year.
- Other Non-Current Liabilities advanced to $467.0 million in Q1 2026, from $304.0 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $638.0 million in Q2 2025 to a low of $225.0 million in Q3 2022.
- A 5-year average of $398.1 million and a median of $411.0 million in 2023 frame the typical range for Other Non-Current Liabilities.
- Peak annual rise in Other Non-Current Liabilities reached 93.47% in 2024, while the deepest fall reached 26.52% in 2024.
- Tracing ELAN's Other Non-Current Liabilities over 5 years: stood at $229.0 million in 2022, then surged by 79.48% to $411.0 million in 2023, then decreased by 26.52% to $302.0 million in 2024, then climbed by 0.66% to $304.0 million in 2025, then soared by 53.62% to $467.0 million in 2026.
- Business Quant data shows ELAN's Other Non-Current Liabilities at $467.0 million in Q1 2026, $304.0 million in Q4 2025, and $607.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 467.00 Mn |
| Dec 31, 2025 | 304.00 Mn |
| Sep 30, 2025 | 607.00 Mn |
| Jun 30, 2025 | 638.00 Mn |
| Mar 31, 2025 | 487.00 Mn |
| Dec 31, 2024 | 302.00 Mn |
| Sep 30, 2024 | 587.00 Mn |
| Jun 30, 2024 | 465.00 Mn |
| Mar 31, 2024 | 474.00 Mn |
| Dec 31, 2023 | 411.00 Mn |
| Sep 30, 2023 | 432.00 Mn |
| Jun 30, 2023 | 411.00 Mn |
| Mar 31, 2023 | 245.00 Mn |
| Dec 31, 2022 | 229.00 Mn |
| Sep 30, 2022 | 225.00 Mn |
| Jun 30, 2022 | 242.00 Mn |
| Mar 31, 2022 | 242.00 Mn |
| Dec 31, 2021 | 262.00 Mn |
| Sep 30, 2021 | 220.00 Mn |
| Jun 30, 2021 | 237.00 Mn |